NEUROCRINE BIOSCIENCES INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for the quarter ending 2020-12-31 was $1.90M, a 73.97% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $2.50M, a 80.92% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for the quarter ending 2020-06-30 was $15.80M, a 267.44% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for the quarter ending 2020-03-31 was $3.30M, a 26.92% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for fiscal 2020 was $23.50M, a 13.92% decline from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for fiscal 2019 was $27.30M, a 7.46% decline from fiscal 2018.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for fiscal 2018 was $29.50M, a 112.78% increase from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, stock options exercised for fiscal 2017 was $13.86M, a 480.08% increase from fiscal 2016.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2020-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $23.50M 10-K · filed 2021-02-05 |
| 2020-09-30 | $2.50M 10-Q · filed 2020-11-09 | $28.90M derived: sum of 4 quarters · filed 2021-02-05 |
| 2020-06-30 | $15.80M 10-Q · filed 2020-08-03 | $39.50M derived: sum of 4 quarters · filed 2021-02-05 |
| 2020-03-31 | $3.30M 10-Q · filed 2020-05-06 | $28.00M derived: sum of 4 quarters · filed 2021-02-05 |
| 2019-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $27.30M 10-K · filed 2021-02-05 |
| 2019-09-30 | $13.10M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $4.30M 10-Q · filed 2020-08-03 | |
| 2019-03-31 | $2.60M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $29.50M 10-K · filed 2021-02-05 | |
| 2018-09-30 | $5.49M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $6.12M 10-Q · filed 2019-11-04 | |
| 2018-03-31 | $16.14M 10-Q · filed 2019-11-04 | |
| 2017-12-31 | $13.86M 10-K · filed 2020-02-07 | |
| 2016-12-31 | $2.39M 10-K · filed 2019-02-08 | |
| 2015-12-31 | $6.30M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $5.56M 10-K · filed 2017-02-14 | |
| 2013-12-31 | $5.30M 10-K · filed 2016-02-11 | |
| 2012-12-31 | $731.00K 10-K · filed 2015-02-09 | |
| 2011-12-31 | $286.00K 10-K · filed 2014-02-11 | |
| 2010-12-31 | $124.00K 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |